PCM
PCRX icon

Prelude Capital Management’s Pacira BioSciences PCRX Stock Holding History

Prelude Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,000
Closed -$97K – 2103
2014
Q3 		$97K Buy
+1,000
New +$97.3K 0.01% 1102

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Prelude Capital Management's PCRX Position: Q2 2026 in Review

Prelude Capital Management reduced its Pacira BioSciences (PCRX) stake by 0.2% in Q2 2026, selling an estimated $2.36K and leaving 50,635 shares worth $1.28M. The position accounts for 0.09% of the portfolio, ranked #246.

Prelude Capital Management first reported a position in PCRX in Q2 2014 and has held it in 27 quarters since. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Prelude Capital Management held 50,635 shares of Pacira BioSciences worth $1.28M as of Q2 2026.
  • Prelude Capital Management sold 100 Pacira BioSciences shares in Q2 2026, an estimated $2.36K.
  • Pacira BioSciences made up 0.09% of Prelude Capital Management's portfolio in Q2 2026, its #246 holding.
  • Prelude Capital Management first reported a position in Pacira BioSciences in Q2 2014 and has held it in 27 quarters since.
  • 254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.